Endpoints News
What FDA reviewers think of peptides Read in browser
Endpoints News
Thursday, 2 July 2026
Thank you for reading, dupa dupackia!
basic
UPGRADE
Manufacturing Day 2026
Biopharma has metabolized the tariff chaos, but the ground keeps shifting under manufacturing and supply chain teams. Hear directly from the experts on what’s changed, what’s working, and what to watch. Join us.
Clinical AI gets real
We’re heading toward a future in which certain parts of medical care are delivered without any humans involved.
Cadence, which raised a $100 million Series C last week, is betting that it can make managing chronic diseases less expensive and more efficient by using AI to automate routine steps, such as monitoring vitals and adjusting medication. 
Today, human clinicians at Cadence get the final say. But founder and CEO Chris Altchek told me he predicts AI agents will be able to carry out some patient-facing tasks without human review in as little as 12 to 24 months.
Regulators are getting more comfortable with clinical uses of AI, and AI models have become more advanced since the end of last year, which makes it easier to ensure they operate safely and hit internal benchmarks, Altchek said.
Just after I spoke with Altchek, news broke that the FDA cleared an AI tool from the startup UpDoc that adjusts diabetes patients’ insulin doses between doctors' appointments, within parameters set by a physician. In a conversation last week, UpDoc CEO Sharif Vakili told Shelby the company had been working with the FDA for three years. Already, it’s deploying the tool at health systems like Cleveland Clinic and UCSF Health.
“The key thing here is a physician must prescribe it — it’s the recognition that a physician needs to be the one who opens the door for the clinical AI to enter the room and join as a care team member," Vakili explained. “There aren’t surprises, it’s not stepping on the toes of physicians.”
Altchek said he expects to see regulators approve AI-only uses in areas like medication adjustment, monitoring vitals and following up on abnormal readings, and lifestyle coaching first. In those cases, there’s clearly defined decision-tree logic AI could follow. However, AI for something like making a diagnosis might take much longer to get approved. Conversations are more open-ended, and there often isn’t a single correct answer. 
“I expect at least a couple to get approved by regulators to remove humans from the loop, but that's going to be a staged, careful, thoughtful process that's studied really rigorously because the stakes are very high,” Altchek said. 
- Ngai
Here’s what’s new
How Butterfly, once known for its handheld ultrasound device, is growing its chip-making business
Nvidia got its start as a gam­ing chip mak­er be­fore me­te­oric suc­cess sell­ing its chips to near­ly every in­dus­try. One health tech com­pa­ny is hop­ing to go down a sim­i­lar route.
FDA reviewers oppose allowing seven peptides for compounding
Ahead of an FDA ad­vi­so­ry com­mit­tee meet­ing to dis­cuss lift­ing re­stric­tions on sev­en pop­u­lar pep­tides, agency re­view­ers have rec­om­mend­ed against in­clud­ing the pep­tides on a list of bulk drug sub­stances that can be used for com­pound­ing.
Bridging coverage
50 Starting Wednesday, eligible Medicare members can get GLP-1 weight loss drugs for $50 a month, as part of Medicare’s Bridge program.
This week in health Тech
Queue, a pharmacy startup building a model that relies on robot kiosk, raised $12.6 million. AlleyCorp led the seed round.

Eating disorder startup Equip Health laid off 4% of its staff, Behavioral Health Business reports. A company representative attributed the cuts to “current market dynamics.” 

OpenLoop bought Hey Revia, a voice AI startup for healthcare providers. (We previously covered when OpenLoop, which powers other telehealth companies, bought nutrition startup Season Health.)
Endpoints News
2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com
web twitter linkedin
Worldwide made. Thanks for reading.
Unsubscribe preferences
Unsubscribe from all newsletters
FT Specialist Logo A service from the Financial Times